NEW YORK, March 09, 2016 -- Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that Monday, March 14, 2016 is the last day to file lead plaintiff papers in the securities lawsuit against Esperion Therapeutics, Inc. (ESPR). Esperion investors are encouraged to contact Scott + Scott at (866) 326-5057 or email [email protected] to discuss their legal rights.
About the Lawsuit
Esperion is a pharmaceutical company that focuses on developing and commercializing oral low-density lipoprotein cholesterol ("LDL-cholesterol") lowering therapies. The securities lawsuit alleges that Esperion issued a press release on August 17, 2015 about its lead product candidate, ETC-1002, that was false and was in conflict with a September 28, 2015 press release.
On August 17, 2015, Esperion stated that it "remains on track to initiate the ETC-1002 Phase 3 development program by the end of 2015" and that, "[b]ased on feedback from the FDA, approval of ETC-1002 in the HeFH and ASCVD patient populations will not require the completion of a cardiovascular outcomes trial (CVOT)."
On September 28, 2015, Esperion stated that "[f]or patients on maximally tolerated statin therapy who require additional LDL-C lowering, Esperion will plan to conduct efficacy and long-term safety trials. FDA has encouraged the Company to initiate a cardiovascular outcomes trial promptly … since any concern regarding the benefit/risk assessment of ETC-1002 could necessitate a completed cardiovascular outcomes trial before approval."
On this news, shares of the Company's stock declined $16.76 per share, or over 47%, to close on September 29, 2015 at $18.33 per share.
What you can do
If you purchased shares of Esperion stock, you may have legal claims against the Company. If you wish to discuss the investigation, or have questions about your legal rights, please contact Geoffrey M. Johnson, Esq. or Joseph Halloran, Esq. by telephone at (866) 326-5057 or by email at [email protected] or [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott + Scott has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California and Ohio.
CONTACT:
Geoffrey M. Johnson, Esq.
Joseph Halloran, Esq.
(216) 229-6088, toll-free (866) 326-5057
[email protected]
[email protected]


SK Hynix to Invest $13 Billion in AI Chip Packaging Facility
How Technology Is Reshaping Modern Business: From Operations to Customer Experience
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic
John Ternus Signals Apple’s Future with Product-First AI Strategy
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 



